THIS PROJECT WILL DEVELOP A SYSTEM FOR THE REMOVAL OF T LYMPHOCYTES OR TUMOR CELLS FROM BONE MARROW USING IMMOBILIZED MONOCLONAL ANTIBODIES.

THIS PROJECT WILL DEVELOP A SYSTEM FOR THE REMOVAL OF T LYMPHOCYTES OR TUMOR CELLS FROM BONE MARROW USING IMMOBILIZED MONOCLONAL ANTIBODIES. THE SELECTIVE REMOVAL OFT CELLS FROM BONE MARROW USING IMMOBILIZED MONOCLONAL ANTIBODIES WILL PROVIDE AN EFFECTIVE SYSTEM FOR ALLOGENIC TRANSPLANT OF BONE MARROW IN A VARIETY OF DISEASE STATES. THIS SYSTEM WILL ALSO SERVE AS A MODEL FOR TUMOR REMOVAL IN AUTOLOGOUS BONE MARROW TRANSPLANT. PREVIOUS WORK HAS DEMONSTRATED THE FEASIBILITY OF SELECTIVELY REMOVING T CELL SUBPOPULATIONS FROM FLOWING, CITRATED, WHOLE HUMAN BLOOD. THIS PHASE I RESEARCH WILL QUANTITATE THE CHARACTERISTICS OFA CONTINUOUS FLOW DEVICE THAT WILL REMOVE LEUKEMIC CELLS FROM BLOOD. THE CAPACITY OF THIS SYSTEM, AND ITS DEPLETION KINETICS AND IMMUNOLOGIC SPECIFICITY, WILL BE DETERMINED. THE ANTIBODIES WILL BE SITE-SPECIFICALLY IMMOBILIZED USING PROPRIETARY CHEMISTRY; SITE-SPECIFIC IMMOBILIZATION CHEMISTRY INVOLVES OXIDATION OF THE OLIGOSACCHARIDE MOIETIESOF THE ANTIBODIES THAT ARE LOCATED IN THE CONSTANT REGION OFTHE ANTIBODY HEAVY CHAIN. COUPLING THE SUBSTRATE TO THE OLIGOSACCHARIDE SHOULD RESULT IN IMMUNOREACTIVE SURFACES WITH EXCELLENT RETENTION OF IMMUNOSPECIFICITY, THEREBY REPRESENTING AN IMPROVED METHOD FOR SEPARATING THE DESIRED CELL POPULATIONS.